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Abstract
Background: Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common pathological features
including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the
close relationship between both diseases supports the study of antidiabetic drugs to limit or slow down brain
pathology in AD. Empagliflozin (EMP) is a sodium-glucose co-transporter 2 inhibitor, the newest class of antidiabetic
agents. EMP controls hyperglycemia and reduces cardiovascular comorbidities and deaths associated to T2D.
Therefore, we have analyzed the role of EMP at the central level in a complex mouse model of AD-T2D.
Methods: We have treated AD-T2D mice (APP/PS1xdb/db mice) with EMP 10 mg/kg for 22 weeks. Glucose, insulin,
and body weight were monthly assessed. We analyzed learning and memory in the Morris water maze and the
new object discrimination test. Postmortem brain assessment was conducted to measure brain atrophy, senile
plaques, and amyloid-β levels. Tau phosphorylation, hemorrhage burden, and microglia were also measured in the
brain after EMP treatment.
Results: EMP treatment helped to maintain insulin levels in diabetic mice. At the central level, EMP limited cortical
thinning and reduced neuronal loss in treated mice. Hemorrhage and microglia burdens were also reduced in EMP-
treated mice. Senile plaque burden was lower, and these effects were accompanied by an amelioration of cognitive
deficits in APP/PS1xdb/db mice.
Conclusions: Altogether, our data support a feasible role for EMP to reduce brain complications associated to AD
and T2D, including classical pathological features and vascular disease, and supporting further assessment of EMP at
the central level.
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Background
Aging remains the main risk factor to suffer Alzheimer’s
disease (AD). However, metabolic disorders, and type 2
diabetes (T2D) concretely, are also relevant contributors
[1]. In this sense, diabetes has been associated with a
1.5- to 2.5-fold greater risk of dementia (for review, see
[2]), and the duration of diabetes has been associated
with reduced hippocampal volumes [3]. While the ultim-
ate pathways responsible for the increased risk of de-
mentia in T2D patients have not been elucidated,
hyperglycemia, vascular alterations, impaired insulin sig-
naling, and affected amyloid clearance have been pointed
out as some of the most relevant underlying possibilities.
Moreover, T2D per se is associated with cognitive dys-
function that can range from subtle diabetes-associated
cognitive decrements to pre-dementia and dementia [4].
On the other hand, AD has no successful treatment, and
therapeutic efforts have been directed towards classical
neuropathological features that include gamma-secretase
modulators, BACE1 inhibitors, immunotherapy, or tau-
based therapies [5–7]. However, different limitations
have been raised [8] reducing the presently approved
treatments to acetylcholinesterase inhibitors and glutam-
ate antagonist memantine [9]. The close relationship be-
tween T2D and AD has resulted in studies based on
metabolic approaches, such as intranasal insulin admin-
istration [10] or antidiabetic agents [11, 12].
Sodium-glucose co-transporter 2 inhibitors (SGLT2i)
are the newest class of oral anti-hyperglycemic agents
approved for the treatment of diabetes mellitus [13].
SGLT2i lower glucose levels independent of insulin, by
limiting tubular glucose reabsorption. Moreover, among
SGLT2i, empagliflozin (EMP) has been deeply analyzed
in the EMPA-REG OUTCOME trial, and EMP limits
renal disease and reduces cardiovascular and total mor-
tality in patients [14, 15]. Following this idea, it has been
suggested that EMP should be considered in patients
with T2D and all forms of atherosclerotic cardiovascular
disease, to reduce mortality and hospitalization for heart
failure [14]. Moreover, the mechanisms responsible for
the reductions in cardiovascular risk with EMP remain
to be fully elucidated, and the protective cardiorenal ef-
fects of EMP seem to be largely independent of its
glucose-lowering effects [15]. It has been suggested that
SGLT2i, as a glucose-lowering therapy, might be associ-
ated with an increased risk of stroke [16]. However it
seems that this only reaches statistical significance in
specific subgroups (patients under 65 years, patients with
increased glycosylated hemoglobin, and patients taking
insulin treatment). Therefore, it is also argued that the
hazard ratio is within the realm of chance [16]. In
addition, long-term treatment with EMP to diabetic
mice has shown that learning and memory are largely
preserved in db/db mice, and cognitive improvement is
accompanied by a reduction of oxidative stress markers
in the brain, including reductions in superoxide, 8-
OHdG or NADPH oxidase subunits, and gp91phox and
p67phox levels. Interestingly, EMP also increased BDNF,
as a key protein promoting memory and neuron survival
[17]. Likewise, EMP may provide neuroprotection in the
diabetic mouse brain by limiting aberrant ultrastructural
remodeling of the neurovascular unit, including the
neuroglia [18]. Studies with rats on a high-fat diet have
also reported the positive effect of SGLT2i treatment on
the brain. Cognitive abilities are improved in the Morris
water maze (MWM), accompanied by reduced oxidative
stress, better insulin signaling, and increased synaptic ac-
tivity in the hippocampus [19]. Also, SGLT2i improve
the performance of mice on a high-fat diet in the new
object discrimination test, along with increased neuro-
genesis in the dentate gyrus and synaptophysin in the
striatum oriens [20]. However, to our knowledge, no
other studies have assessed the role of SGLT2i on cen-
tral complications associated to AD and T2D, such as
amyloid pathology, microglia activation, spontaneous
bleeding, or cognitive deficits. Therefore, in this study,
we treat a clinically relevant mixed murine model of AD
and T2D (APP/PS1xdb/db mouse) [21, 22] with EMP
from 4 to 26 weeks of age, when both AD and T2D are
fully established in our mouse model, to assess the direct
effect of long-term EMP treatment on brain pathology.
As it could be expected, EMP significantly helped to
control metabolic alterations. By the end of the treat-
ment, brain atrophy and neuronal loss were significantly
reduced in diabetic mice, as well as spontaneous bleed-
ing and microglia burden (Iba1+), as a feasible marker of
brain inflammation. On the other hand, EMP treatment
also reduced senile plaque (SP) burden and amyloid-β
(Aβ) levels in AD mice. Moreover, behavioral assessment
revealed an overall improvement of learning and mem-
ory in treated animals, supporting a role for EMP in
brain pathology and behavioral consequences associated
with AD and T2D.
Methods
Animals, treatments, and metabolic assessment
APP/PS1xdb/db mice were generated in our animal fa-
cility by crossing APPswe/PS1dE9 (APP/PS1) [23] and
db/db [24] mice, as described [21, 22]. Control, APP/
PS1, db/db, and APP/PS1xdb/db mice were randomly
divided into groups, and EMP (10 mg/kg) [25] was ad-
ministered in the diet, as previously described [12], from
4 to 26 weeks of age. Due to the limited amount of ani-
mals harboring both AD and T2D, males and females
were included in the study, as previously done in similar
studies [10, 19, 20]. Body weight as well as glucose and
insulin levels was measured before treatment and every
4 weeks until sacrifice at 26 weeks. Immediately after
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sacrifice, the brains were harvested and weighted. The
right hemispheres were dissected and snap-frozen at −
80° until use. The left hemispheres were fixed in parafor-
maldehyde for 2 weeks before 30-μm sections were cut.
All experimental procedures were approved by the Ani-
mal Care and Use Committee of the University of Cadiz,
in accordance with the Guidelines for Care and Use of
experimental animals (European Commission Directive
2010/63/UE and Spanish Royal Decree 53/2013).
Morris water maze
Spatial memory was assessed 2 weeks before the sacrifice
as described [26]. The acquisition phase consisted of 4
trials/day for 4 consecutive days with the platform sub-
merged in quadrant 2. The time limit was 60 s/trial, with
a 10-min inter-trial interval. Retention phases were pre-
formed 24 and 72 h after completing the acquisition.
The platform was removed, and mice were allowed to
swim for 60 s. The time required to locate the platform
in the acquisition phase, percentage of time spent in
quadrant 2 during the retention phase, and swimming
speed were analyzed using the Smart software (Panlab,
Spain).
Motor activity and new object discrimination test
Motor activity assessment and new object discrimination
(NOD) commenced after completing the MWM test.
Motor activity was assessed by measuring the distance
traveled by the mice for 30 min in the open field box.
The new object discrimination commenced the next day,
and episodic memory paradigms “what,” “where,” and
“when” were analyzed as previously described [22].
Cresyl violet staining
Cresyl violet staining was used to unspecifically label
neurons and identify brain regions of interest. Sections
located 1 mm apart (from 1.5 to − 3.5 mm from the
bregma) were selected, dehydrated in 70% ethanol for
15 min, and incubated in cresyl violet as previously de-
scribed [12]. Images were acquired in an optical Olym-
pus Bx60 microscope with an Olympus DP71 camera.
Cell F (Olympus, Hamburg, Germany) and ImageJ soft-
ware were used to measure cortical and hippocampal
sizes.
NeuN/DAPI staining
Contiguous sections to those used for cresyl violet stain-
ing were incubated with anti-NeuN (Chemicon, CA,
USA) (1:200) (Invitrogen, Carlsbad, CA, USA) and Alexa
Fluor 594 (Molecular Probes, OR, USA) (1:1000) anti-
bodies, followed by DAPI 1 mg/ml (Sigma, Spain) (1:
3000) counterstain. SP were stained with thioflavin S
(Sigma, OR) (0.01%) in H2O/ethanol (1:1) for 10 min.
The percentage of NeuN-positive cells (normalized by
total cells stained with DAPI) was quantified in the cor-
tex using ImageJ software as described [12].
Prussian blue staining
Contiguous sections to those used for NeuN/DAPI
staining were incubated with Prussian blue iron staining
and neutral red counterstaining, as previously described
[22], to analyze spontaneous hemorrhages. The ImageJ
software was used to quantify hemorrhage burden, dens-
ity, and individual hemorrhage size in the cortex and
hippocampus.
Microglia immunostaining
Sections were pre-treated in 70% formic acid and incu-
bated with anti-Iba1 (Wako, Osaka, Japan) (1:1000) and
anti-Aβ (4G8, Covance, Greenfield, IN, USA) (1:2000)
antibodies overnight at 4 °C in 0.5% BSA, followed by in-
cubation with Alexa Fluor 488 and Alexa Fluor 594
(Molecular Probes, OR, USA) (1:1000). Sections were
photographed using a Laser Olympus U-RFL-T fluores-
cent microscope (Olympus, Japan) and MMIcellTools
software. Microglia burden in SP-free areas as well as in
the close proximity of SP (up to 50 μm) was quantified
as previously described [12].
SP staining
SP burden was analyzed in the cortex and hippocampus
after 4G8 immunostaining and thioflavin S staining. Sec-
tions were pre-treated in 70% formic acid and incubated
with 4G8 (Covance, Greenfield, IN, USA) antibody (1:
2000) followed by Alexa Fluor 594 (Molecular Probes,
OR, USA) antibody (1:1000). Sections were further incu-
bated in thioflavin S (Sigma, OR, USA) (0.01%) in H2O/
ethanol 1:1, mounted, and photographed using a Laser
Olympus U-RFL-T fluorescent microscope (Olympus,
Japan) and MMIcellTools software. The ImageJ software
was used for burden analysis.
Amyloid beta levels
Soluble and insoluble (formic fraction) Aβ40 and Aβ42
levels were measured in the cortex and hippocampus by
colorimetric ELISA kits (Wako, Japan) [12]. Absorbance
was measured at 450 nm in a spectrophotometer
(MQX200R2, BioTek Instruments, Burlington, VT, USA).
Total tau and phospho-tau levels
Total tau and tau phosphorylation levels were measured
in cortical and hippocampal samples [21]. Phospho-tau
clone AT8 (1:1000) (Fisher Scientific, MA, USA) and
anti-total tau (1:1000) (DAKO, Denmark) antibodies
were used. After normalizing to β-actin (1:2.500.000)
(Sigma, USA), optical density was semi-quantified using
the ImageJ software. Phospho-tau/total tau ratios were
represented as the percentage of control values.
Hierro-Bujalance et al. Alzheimer's Research & Therapy           (2020) 12:40 Page 3 of 13
Statistical analysis
Two-way ANOVA was used for metabolic follow-up and
MWM studies. One-way ANOVA for independent sam-
ples followed by Tuckey b or Tamhane tests or Kruskal-
Wallis for independent samples followed by Mann-
Whitney U test with Bonferroni adjustment were used
in the rest of the experiments. The SPSS v.24 software
was used for all statistical analysis.
Results
EMP ameliorates metabolic alterations in db/db and APP/
PS1xdb/db mice
Postprandial glucose levels were monitored every 4 weeks,
from 4 to 26 weeks of age, as detected by 2-way ANOVA
(groupXweek) ([F(35, 334) = 2.88, **p < 0.01], statistical
power 1.000). No differences in glucose levels were
present by 6 weeks of age (statistical power 0.317). Severe
hyperglycemia was observed in diabetic mice (db/db and
APP/PS1xdb/db mice) by 10 weeks of age. While glucose
levels were still increased, EMP treatment significantly re-
duced hyperglycemia in db/db and APP/PS1xdb/db mice,
4 weeks after the commencement of the treatment. Gly-
cemia control was maintained in diabetes-treated mice
until the end of the study at 26 weeks of age (Fig. 1a) (stat-
istical power 1.00). No differences were detected by 2-way
ANOVA (groupXweek) ([F(35, 424) = 1.21, p = 0.189], statis-
tical power 0.965) when insulin levels were compared.
However, individual weekly assessment revealed that insu-
lin levels were significantly increased in db/db and APP/
PS1xdb/db mice along the study. EMP treatment helped
to maintain elevated plasmatic insulin in an attempt to
control hyperglycemia in diabetic mice, up to 26 weeks of
age. These data support a feasible role for EMP to reduce
pancreatic exhaustion in db/db and APP/PS1xdb/db mice
(statistical power > 0.899) (Fig. 1b). When we analyzed the
body weight, we detected a significant groupXweek effect
([F(35, 455) = 5.70, **p < 0.01], statistical power 1.000). Body
weight was significantly higher in diabetic mice from 6
weeks of age; however, as the disease progresses, the cach-
ectic effect of diabetes is observed. EMP treatment con-
tributed to maintain body weight in db/db and APP/
PS1xdb/db mice (statistical power > 1.00) (Fig. 1c), as pre-
viously observed with other antidiabetic treatments [21,
22].
EMP improves learning and memory in AD, T2D, and AD-
T2D mice
We used a very demanding version of the NOD task, and
we observed that episodic memory was slightly affected in
APP/PS1 and db/db mice at 26 weeks of age, and the im-
pairment was more severe in APP/PS1xdb/db mice. EMP
treatment significantly improved the performance in the
NOD test for all paradigms under study (“what,” “where,”
and “when,” statistical power > 0.921) (Fig. 2a).
Acquisition in the MWM revealed that APP/PS1 and
db/db mice were cognitively impaired, and a synergistic
effect was observed in APP/PS1xdb/db mice. EMP treat-
ment reduced acquisition times in APP/PS1, db/db, and
APP/PS1xdb/db mice. We detected a significant day-
Xgroup effect by 2-way ANOVA for independent samples
([F(21, 1150) = 1.87, *p = 0.01], statistical power 0.986), and
individual day assessment confirmed the improvement as
trials were conducted (statistical power > 0.980) (Fig. 2b).
Along retention 1 (24 h after completing the acquisition
phase), the time spent in quadrant 2 (where the platform
used to be located) was reduced for APP/PS1, db/db, and
APP/PS1xdb/db mice, whereas EMP treatment amelio-
rated this situation; however, no statistical differences
were detected among the groups (statistical power =
0.640) (Fig. 2c). On retention 2 (72 h after completing the
Fig. 1 EMP treatment limits metabolic alterations in db/db and APP/PS1xdb/db mice. a Long-term EMP treatment significantly reduced
postprandial glucose levels in diabetic mice. No differences were detected at week 6 ([F(7, 36)=0.864, p = 0.543], statistical power 0.317), although
differences were detected from week 10 to week 22 (week 10 [F(7, 33)=18.91], week 14 [F(7, 67) = 32.92], week 18 [F(7, 69) = 31.68], week 22 [F(7, 66) =
25.12]; ‡‡p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and APP/PS1xdb/db-EMP; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/
PS1-EMP]). b When insulin levels were analyzed, individual weekly assessment revealed that EMP treatment helped to maintain high insulin levels
in db/db and APP/PS1xdb/db mice as the disease progresses (week 6 [F(7, 75) = 2.29, p = 0.036], week 10 [F(7, 74) = 4.47], week 14 [F(7, 69) = 5.23],
week 18 [F(7, 68) = 5.42], week 22 [F(7, 69) = 4.49], week 26 [F(7, 69) = 6.89];
╫╫p < 0.01 vs. control, control-EMP, and APP/PS1]; ‡‡p < 0.01 vs. control,
control-EMP, APP/PS1, APP/PS1-EMP, and db/db; ††p < 0.01 vs. control, control-EMP, APP/PS1, and APP/PS1-EMP; ##p < 0.01 vs. control, control-
EMP, APP/PS1, APP/PS1-EMP, db/db, and APP/PS1xdb/db). c Body weight was maintained by EMP, as revealed by weekly assessment (week 6 [F(7,
75) = 6.21], week 10 [F(7, 73) = 34.13], week 14 [F(7, 76) = 42.39], week 18 [F(7, 77) = 44.34], week 22 [F(7, 77) = 55.71], week 26 [F(7, 77) = 52.55];
††p < 0.01
vs. control, control-EMP, APP/PS1, and APP/PS1-EMP]; ##p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and db/db; ††p < 0.01 vs. control,
control-EMP, APP/PS1, and APP/PS1xdb/db; **p < 0.01 vs. rest of the groups) (control n = 13, control-EMP n = 10, APP/PS1 n = 9, APP/PS1-EMP n =
11, db/db n = 11, db/db-EMP n = 10–12, APP/PS1xdb/db n = 9, APP/PS1xdb/db-EMP n = 10)
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acquisition phase), memory was compromised in APP/
PS1, db/db, and APP/PS1xdb/db mice, when compared
with wild-type animals. Altered cognitive abilities in db/db
and APP/PS1xdb/db mice were reversed by EMP treat-
ment (statistical power = 0.987) (Fig. 2c).
When we measured the total distance traveled, to ana-
lyzed motor activity, no significant differences were ob-
served (control, 12052.90 ± 1329.56; control-EMP,
12003.58 ± 681.15; APP/PS1, 11289.92 ± 1012.64; APP/
PS1-EMP, 10351.01 ± 974.93; db/db, 11859.18 ± 2197.19;
db/db-EMP, 9968.56 ± 763.54; APP/PS1xdb/db,
13422.28 ± 2203.02; and APP/PS1xdb/db-EMP, 8268.43 ±
525.504; [F(7, 69) = 1.57, p = 0.157], statistical power 0.614),
supporting that observed differences in cognitive tests
were not derived from altered motor activity.
Brain atrophy is reduced in diabetic mice after EMP
treatment
Brain atrophy in db/db and APP/PS1xdb/db mice was
improved after EMP treatment, when the hemisection
and cortical areas were measured (statistical power >
0.970) (Fig. 3a, c). While a similar profile was observed
in the hippocampus, differences did not reach statistical
significance (statistical power 0.276) (Fig. 3a). Similarly,
cortical thickness was significantly reduced in diabetic
mice, and EMP helped to reverse this situation (statis-
tical power 0.884) (Fig. 3b, c). To further characterize
the observed atrophy, we also analyzed the neuronal
density in the cortex. NeuN/DAPI ratio was reduced in
the cortex from APP/PS1, db/db, and APP/PS1xdb/db
mice, both in the proximity of SP and far from plaques,
while EMP treatment significantly reversed this situation
(statistical power > 0.959) (Fig. 3d, e).
Spontaneous bleeding is reduced by EMP treatment
As previously described, the burden of spontaneous
hemorrhages was higher in db/db and APP/PS1xdb/
db mice [21, 22], whereas EMP treatment counterba-
lanced this situation (statistical power = 0.997) (Fig. 4a,
b). This effect was due to a reduction in hemorrhage
density, while individual hemorrhage size was not af-
fected (data not shown). We observed a similar pro-
file in the hippocampus, although differences did not
reach statistical significance (statistical power = 0.723)
(Fig. 4a).
Fig. 2 Cognitive impairment in APP/PS1xdb/db mice was ameliorated by EMP treatment. a EMP treatment significantly improved the
performance in the NOD test for all paradigms under study (“what” [F(7, 207) = 2.88], “where” [F(7, 208) = 3.17], “when” [F(7, 214) = 3.79];
##p < 0.01 vs.
control, control-EMP, and APP/PS1-EMP; ††p < 0.01 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db, and db/db-EMP; ‡‡p < 0.01 vs. control,
control-EMP, APP/PS1, APP/PS1-EMP, db/db-EMP, and APP/PS1xdb/db-EMP). b In the MWM, EMP treatment reduced acquisition times in APP/PS1,
db/db, and APP/PS1xdb/db mice (day 1 [F(7, 298)=3.85], day 2 [F(7, 288) = 14.33], day 3 [F(7, 280) = 13.27], day 4 [F(7, 284) = 18.24]; **p < 0.001 vs. the rest
of the groups; ††p < 0.001 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, and db/db-EMP; ╫╫p < 0.01 vs. control, control-EMP, and APP/PS1-
EMP; p < 0.01 vs. control and control-EMP). c EMP ameliorated the impairment observed along retention 1 (24 h);, however no statistical
differences were detected among the groups [F(7, 69) = 1.65, p = 0.134]. On retention 2 (72 h), reduced cognitive abilities in db/db and APP/
PS1xdb/db mice were reversed by EMP treatment [F(7, 68) = 4.40,
‡‡p < 0.001 vs. control and control-EMP] (control n = 11, control-EMP n = 13, APP/
PS1 n = 10, APP/PS1-EMP n = 10, db/db n = 9, db/db-EMP n = 10, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 9)
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Iba1+ burden is reduced after EMP treatment
Cortical microglia burden was significantly lower in
APP/PS1xdb/db mice in the close proximity to SP
(statistical power 0.997) in line with previous observa-
tions [21, 22]. In SP-free areas, microglia burden was
increased in db/db and APP/PS1xdb/db mice and
EMP treatment reduced microglia burden (statistical
power 1.00) (Fig. 4c, d). While a similar profile was
observed in the hippocampus, microglia burden was
not significantly affected in areas close to plaques
(statistical power = 0.546). In SP-free areas, increased
microglia burden in db/db and APP/PS1xdb/db mice
was slightly reduced after EMP treatment (statistical
power 1.000) (Fig. 4c).
EMP treatment reduced amyloid pathology in APP/PS1
and APP/PS1xdb/db mice
SP burden was significantly lower in the cortex from APP/
PS1xdb/db mice, as previously described in this animal
model [21, 22]. EMP treatment slightly reduced SP burden
in APP/PS1 and APP/PS1xdb/db mice (statistical power
1.000) (Fig. 5a), although SP were slightly larger in APP/
PS1-EMP mice (statistical power > 0.996) (Fig. 5a). How-
ever, SP density was reduced by EMP treatment in APP/
PS1 animals (statistical power 1.000) (Fig. 5a, b). To a
lesser extent, we observed a similar trend when we ana-
lyzed SP burden (statistical power > 0.946), density (statis-
tical power > 0.995), and individual plaque size in the
hippocampus (statistical power > 0.267) (Fig. 5c).
Fig. 3 Brain atrophy was ameliorated by EMP treatment. a Brain atrophy in db/db and APP/PS1xdb/db mice was improved after EMP treatment,
when the hemisection size and cortical areas were analyzed (hemisection [F(7, 205) = 6.23]; hemicortex [F(7, 191) = 3.59];
††p < 0.01 vs. control,
control-EMP, APP/PS1, and APP/PS1-EMP]; ┬p < 0.01 vs. control). While a similar profile was observed in the hippocampus, differences did not
reach statistical significance [F(7, 107) = 0.718; p = 0.657] (control n = 7, control-EMP n = 9, APP/PS1 n = 6, APP/PS1-EMP n = 5, db/db n = 6, db/db-
EMP n = 7, APP/PS1xdb/db n = 6, APP/PS1xdb/db-EMP n = 5). b Cortical thickness was also improved after EMP treatment [F(7, 419)=2.53;
♯♯p < 0.01
vs. APP/PS, db/db-EMP, and APP/PS1xdb/db-EMP]. c Illustrative example of cresyl violet staining where cortical thinning observed in db/db and
APP/PS1xdb/db mice is restored by EMP treatment. Scale bar = 125 μm. d NeuN/DAPI ratios were reduced in the proximity and far from SP, and
EMP treatment reversed this situation (close to plaques [F(3, 933) = 6.017,
††p < 0.001 vs. APP/PS1-EMP and APP/PS1xdb/db-EMP; ‡‡p < 0.01 vs. APP/
PS1xdb/db-EMP]; far from plaques [F(7, 3029) = 15.86, p < 0.001 vs. control, control-EMP, APP/PS1, APP/PS1-EMP, db/db-EMP, and APP/PS1xdb/
db-EMP; ##p < 0.01 vs. control-EMP and APP/PS1-EMP]) (control n = 5, control-EMP n = 4, APP/PS1 n = 5, APP/PS1-EMP n = 4, db/db n = 5, db/db-
EMP n = 4, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 4). e Illustrative example of NeuN/DAPI staining in the proximity and far from SP in the
cortex. Scale bars = 25 μm
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Fig. 4 (See legend on next page.)
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We also assessed amyloid levels in the cortex and the
hippocampus. In line with previous observations, we de-
tected a shift in the natural history of Aβ deposition, and
soluble, more toxic species were favored in APP/
PS1xdb/db mice, while insoluble Aβ levels were lower,
in line with our observations in SP quantification. EMP
treatment reduced soluble Aβ40 levels in the cortex
(statistical power 0.800) (Fig. 5d). The same profile was
observed for Aβ40 levels in the hippocampus (statistical
power 0.133), as well as for soluble Aβ42 levels (both in
the cortex and hippocampus); however, differences did
not reach statistical significance (statistical power >
0.206) (Fig. 5d). EMP also reduced insoluble Aβ40 levels
in the cortex (statistical power 0.923) (Fig. 5d), whereas
no differences were observed when insoluble Aβ42 levels
were compared (statistical power 0.336). Insoluble Aβ40
(statistical power 0.572) and Aβ42 (statistical power
0.357) levels were not significantly affected in the hippo-
campus (Fig. 5d).
EMP treatment limits tau phosphorylation
Tau phosphorylation was increased in APP/PS1, and
more robustly in db/db and APP/PS1xdb/db mice, as
previously described. EMP treatment ameliorated this
situation in the cortex from db/db-treated mice (χ2 =
32.11, p = 0.008, ##p < 0.01 vs. control, statistical power
0.934) (supplementary figure 1a and b). A similar profile
was observed in the hippocampus, although differences
did not reach statistical significance (χ2 = 3.74, p = 0.809,
statistical power 0.337) (supplementary figure 1a and b).
Discussion
AD has no successful treatment, and patients are in a
tremendous need of new therapeutic approaches. The
close relationship between T2D and AD has been previ-
ously suggested as a relevant target to slow down or re-
duce brain complications [12, 27, 28]. Following this
idea, SGLT2i are the newest oral antidiabetic drugs, and
previous studies have focused on characterizing
metabolic and peripheral action of these agents. Among
SGLT2i, EMP has been shown to control metabolic-
related alterations and reduce mortality in patients [29].
However, the role of SGLT2i on the central nervous sys-
tem has been scarcely addressed in diabetes models [17–
19], and to our knowledge, no specific studies have ana-
lyzed SGLT2i on AD central pathology.
As expected, EMP ameliorated metabolic alterations,
and glucose levels were reduced in diabetic mice. SGLTi
mechanism of action is insulin independent; however,
since db/db mice are a leptin receptor functional KO
model, they are severely diabetic and glucose levels can-
not be normalized by EMP treatment. However, we de-
tected that diabetic hyperinsulinemia was longer
maintained after EMP treatment, in a similar trend to that
previously described in SGLTi-treated db/db mice [30].
These observations are consistent with the maintenance
of β-pancreatic activity and insulin levels in diabetic mice
after the SGLTi administration [31]. While body weight
control has been observed in patients treated with SGLT2i
[32, 33], in our hands, long-term EMP treatment main-
tained body weight, as previously described in db/db cach-
ectic mice treated with SGLTi [30].
Postmortem assessment of EMP-treated mice revealed
that brain atrophy observed in diabetic animals was sig-
nificantly ameliorated. Our previous characterization of
db/db [26] and APP/PS1xdb/db mice [21, 22] revealed a
preferential affectation of the cortex in these animal
models with a slight compromise of the hippocampus.
Whereas neuronal loss is not observed in APP/PS1 ani-
mals [34], when APP/PS1 mice are crossed with db/db
mice, brain atrophy is observed as the disease progresses
in APP/PS1xd/db mice, making the model more com-
plex, and better resembling actual AD pathology. In our
hands, EMP treatment also helped to keep NeuN/DAPI
ratios, suggesting a role for EMP in maintaining the neu-
roregenerative capacity both in the proximity and far
from senile plaques. On the whole, EMP treatment suc-
cessfully limits cortical thinning and maintains neuronal
(See figure on previous page.)
Fig. 4 Spontaneous bleeding and inflammation were reduced after EMP treatment. a EMP reduced hemorrhage burden in the cortex, and while
a similar profile was observed in the hippocampus, differences were not statistically significant (cortex [F(7, 262) = 2.65,
†p = 0.011 vs. control,
control-EMP, APP/PS1, and APP/PS1-EMP]; hippocampus [F(7, 118) = 01.85, p = 0.081]) (control n = 8, control-EMP n = 6, APP/PS1 n = 5, APP/PS1-EMP
n = 4, db/db n = 7, db/db-EMP n = 6, APP/PS1xdb/db n = 4, APP/PS1xdb/db-EMP n = 6). b Illustrative example of Prussian blue staining in all
groups under study. Green arrows point at individual hemorrhages. Scale bar = 100 μm. c Cortical microglia burden was lower in the proximity of
SP in APP/PS1xdb/db mice ([F(3, 534) = 7.036],
‡‡p < 0.01 vs. APP/PS1 and APP/PS1-EMP, ┬┬p < 0.01 vs. APP/PS1]), while in SP-free areas, increased
burden was reduced after EMP treatment ([F(7, 4465)=137.36, **p < 0.01 vs. the rest of the groups, p < 0.01 vs. control, control-EMP, APP/PS1,
APP/PS1-EMP, db/db-EMP, and APP/PS1xdb/db-EMP; ††p < 0.01 vs. control, control-EMP, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ##p < 0.01 vs.
APP/PS1-EMP and APP/PS1xdb/db-EMP]). A similar profile was observed in the hippocampus, and microglia burden was reduced after EMP
treatment in SP-free areas (close to plaques ([F(3, 39)=2.21, p = 0.91]); far from plaques [F(7, 768) = 23.79,
╫╫p < 0.01 vs. control, control-EMP, APP/
PS1, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ††p < 0.01 vs. control, control-EMP, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ♯♯p < 0.01 vs. control and
control-EMP]) (control n = 5, control-EMP n = 5, APP/PS1 n = 5, APP/PS1-EMP n = 4, db/db n = 6, db/db-EMP n = 4, APP/PS1xdb/db n = 4, APP/
PS1xdb/db-EMP n = 5). d Illustrative example of the cortical areas immunostained for Iba-1 (green) and SP (4G8, red). Circles point out
representative regions close and far from SP. Scale bar = 125 μm
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Fig. 5 (See legend on next page.)
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density after long-term administration, as previously de-
scribed with other antidiabetic treatments [12, 35, 36].
Vascular disease has been closely associated to AD
and T2D, and a synergistic effect has been reported
when both pathologies coexist. Spontaneous bleeding is
a neuropathological feature that affects db/db mice and
more severely APP/PS1xdb/db animals, reproducing
brain small vessel disease. In our hands, vascular disease
parameters did not correlate with NeuN/DAPI ratios
(data not shown), and it is feasible that a combination of
all alterations (vascular damage, microglia activation,
amyloid pathology, and metabolic alteration) is synergis-
tically responsible for observed cognitive impairment.
However, Bello-Chavolla et al. [37] have recently
reviewed neuroimaging and neuropathology studies sup-
porting a role for neurodegeneration and cerebrovascu-
lar lesions, specifically small vessel disease, in the onset
of dementia, consistent with the increased risk of de-
mentia in T2D patients. EMP treatment significantly
ameliorated the microhemorrhage burden in the cortex,
the most severely affected brain region. These observa-
tions are in agreement with previous ultrastructural
studies, showing that EMP treatment reduces attenu-
ation and/or loss of pericytes as well as endothelial cell
tight and adherents junctions and prevents endothelial
dysfunction in different diabetic models [18, 38].
Inflammation is a major component, both in T2D and
AD [39], that may underlie the close relationship between
T2D and AD [40]. Likewise, hypoglycemic agents show
anti-inflammatory activity [41]. Moreover, these anti-
inflammatory effects are also detected at the central level
with metformin [42], liraglutide [43], multitarget agents
[28], or combined therapies [12]. In our hands, EMP also
reduced microglia burden in the parenchyma from db/db
and APP/PS1xdb/db mice. Our studies are limited to
microglia assessment, by Iba1 immunostaining, and there-
fore, the whole complexity of the inflammatory process is
not covered. However, our observations are in accordance
with other studies showing that EMP may reduce oxida-
tive stress, astrocyte activation, and inflammation in dia-
betic models [18, 38]. While the underlying mechanisms
have not been completely elucidated, SGLT2i anti-
inflammatory activity might be related to increased levels
of anti-inflammatory ketone bodies, decreased interface of
immune cells with glucose, or reduced insulin and uric
acid levels, among others [44].
Amyloid pathology is altered in our AD-T2D model,
and more toxic soluble Aβ species are favored in the
mixed model; nevertheless, insoluble Aβ is reduced [21,
22]. These observations support a shift in the natural
history of Aβ deposition, and whereas soluble Aβ species
tend to be increased, insoluble Aβ and SP are reduced.
These data are in line with those by Niedowicz et al.
[45] reporting an increase of oligomeric Aβ without an
effect on Aβ deposition, when AD and T2D are set to-
gether, in a similar mouse model. Other studies have re-
ported limited changes in total Aβ levels and increased
amyloid angiopathy in young APP23xob/ob mice [46].
Likewise, studies with APP/PS1 mice on a high-fat diet
or APP/PS1 mice crossbred with pancreatic insulin-like
growth factor 2 overexpressing mice have failed to in-
crease Aβ burden in the brain [47]. We observed that
EMP treatment reduces SP density, and an overall re-
duction of soluble and insoluble Aβ levels is detected in
the cortex and the hippocampus from EMP-treated
mice. Whereas we cannot point towards a specific mech-
anism, other antidiabetic treatments have also shown to
reduce amyloid pathology [21, 48, 49], based not only on
metabolic control but also on their effects on oxidative
stress, inflammation, or the blood-brain barrier.
Tau phosphorylation is also increased in diabetic mice,
and although EMP reverted this situation in db/db mice,
the overall effect was limited. Nevertheless, it also needs
to be taken into consideration that APP/PS1 mice do not
present overt tau pathology, limiting the outcomes at this
level. It seems well established that insulin resistance may
(See figure on previous page.)
Fig. 5 Amyloid pathology is reduced by EMP treatment. a SP burden was lower in APP/PS1xdb/db mice when compared with APP/PS1 animals.
EMP treatment slightly reduced SP burden in the cortex after TS and 4G8 staining (TS [F(3, 107) = 20.55], 4G8 [F(3, 104) = 11.89];
††p < 0.01 vs. APP/PS1
and APP/PS1-EMP). While individual SP size was increased in APP/PS-EMP mice (TS [F(3, 5191) = 8.98], 4G8 [F(3, 5039) = 21.11];
‡‡p < 0.01 vs. APP/PS1-
EMP; ††p < 0.01 vs. APP/PS1 and APP/PS1-EMP), EMP treatment reduced SP density (TS [F(3, 107) = 19.74], 4G8 [F(3, 107) = 17.81];
‡‡p < 0.01 vs. APP/
PS1; ††p < 0.01 vs. APP/PS1 and APP/PS1-EMP). To a lesser extent, we observed a similar trend when we analyzed SP burden in the hippocampus
(TS [F(3, 49) = 8.01], 4G8 [F(3, 49) = 6.08];
‡‡p < 0.01 vs. APP/PS1]), SP density (TS [F(3, 50) = 11.57], 4G8 [F(3, 50) = 9.42];
‡‡p < 0.01 vs. APP/PS1), and
individual plaque size (TS [F(3, 643) = 0.975, p = 0.404]; 4G8 [F(3, 638) = 2.39, p = 0.067]) (APP/PS1 n = 5, APP/PS1-EMP n = 5, APP/PS1xdb/db n = 5,
APP/PS1xdb/db-EMP n = 5). b Illustrative example of cortical regions stained with TS and 4G8 where reduced SP density can be observed after
EMP treatment. Scale bar = 50 μm. c A similar profile was observed in the hippocampus when we measured SP burden, density, and individual SP
size (‡‡p < 0.01 vs. APP/PS1) (APP/PS1 n = 5, APP/PS1-EMP n = 5, APP/PS1xdb/db n = 5, APP/PS1xdb/db-EMP n = 5). d EMP treatment reduced
soluble Aβ40 levels in the cortex ([F(3, 27) = 4.20, ‡p = 0.015 vs. APP/PS1xdb/db]). While a similar trend was observed in the hippocampus,
differences were not statistically significant ([F(3, 26)=0.479, p = 0.7]). No differences were observed for soluble Aβ42 levels in the cortex ([F(3, 27) =
0.832, p = 0.488]) or the hippocampus ([F(3, 26) = 1.02, p = 0.397]). EMP also reduced insoluble Aβ40 levels in the cortex ([F(3, 25) = 5.98, **p = 0.003
vs. the rest of the groups]), while differences did not reach statistical significance for insoluble Aβ40 in the hippocampus ([F(3, 22) = 2.68, p = 0.072])
as well as for insoluble Aβ42 levels (cortex [F(3, 27) = 1.43, p = 0.254]; hippocampus [F(3, 26) = 1.54, p = 0.228]) (APP/PS1 n = 7, APP/PS1-EMP n = 9,
APP/PS1xdb/db n = 7, APP/PS1xdb/db-EMP n = 7)
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increase tau pathology by interfering the balance between
tau kinases and phosphatases Tau also modulates insulin
signaling [50], contributing to the cross-talk between both
pathologies. We have previously observed similar out-
comes with other antidiabetic treatments [12]. In line with
these observations, pioglitazone has also been shown to
reduce tau oligomerization, phospho, and total tau levels,
and it also inactivates glycogen synthase kinase 3β in pri-
mary neuronal cultures [51].
As previously shown, AD-T2D mice present severe
learning and memory compromises [21, 22]. Leptin sig-
naling dysfunction has been associated to central com-
plications, including cognitive impairment [52] or long-
term potentiation [53], and therefore, we cannot exclude
our findings that it might be at least partially due to al-
tered leptin signaling. However, we observed a better
performance of EMP-treated mice in the MWM. Other
studies have shown the positive effect of antidiabetic
agents in learning and memory [54], and SGLT2i have
also been shown to improve cognitive impairment in
other metabolic disease models [17, 19].
While to our knowledge, there are no previous studies
analyzing the effect of SGLT2i on AD animal models,
the beneficial effect of SGLT2i canagliflozin in rats with
scopolamine-induced memory impairment has been re-
ported. In this animal model, improvement in the
MWM is attributed to the inhibition of acetylcholin-
esterase activity and monoamine levels in the brain.
Canagliflozin might act as a dual acetylcholinesterase
and SGLT2i [55], supporting a dual role for SGLT2i at
the central level [56, 57] and opening an interesting
venue, since acetylcholinesterase inhibitors, and NMDA
receptor antagonist memantine, are the only FDA-
approved options to treat AD. In our learning and mem-
ory studies, we additionally used a very demanding ver-
sion of the NOD task, which allows the assessment of
episodic memory [58]. We also observed an overall im-
provement after EMP treatment, in line with previous
studies [59]. Cognitive enhancement cannot be attrib-
uted to a single effect, however it is feasible that by redu-
cing microglia burden, vascular damage, and amyloid
pathology, EMP consequently improves learning and
memory in AD-T2D mice. Also, the large number of
groups in the study also limits the detection of post hoc
differences, making it hard to disentangle the direct ef-
fect of EMP on AD mice. However, when we analyzed
AD mice (APP/PS1 and APP/PS1-EMP) separately, we
observed an overall improvement of different patho-
logical features, including cortical NeuN/DAPI ratio,
microglia burden in the proximity of SP, or SP density
in the cortex and hippocampus, accompanied by better
performance in the MWM test, supporting a role for
EMP specifically associated to AD pathology in APP/PS1
mice. It also needs to be pointed out that whereas APP/
PS1 mice show limited behavioral complications by 6
months of age, db/db mice present severe pathology that
limits the chances to take APP/PS1xdb/db mice to older
ages. This situation also precludes the possibility to obtain
relevant information after the long-term evolution of both
pathologies, as commonly observed in the clinic. Neverthe-
less, APP/PS1xdb/db mice are a relevant model that offers
the possibility of assessing both AD and T2D pathological
features, offering a more complex version of the process.
Conclusion
Altogether, our results suggest a role for EMP to reduce
brain complications associated to T2D and AD, including
classical AD features and vascular disease. Whereas these
are initial studies on animal models, the close relationship
between AD and T2D may support further assessment of
T2D patients treated with EMP, in order to provide new
insights into the effects of EMP on the brain.
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